Abstract: Formulations of 3-((3-(4-(2-(isobutylsulfonyl)phenoxy)-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-5-yl)methyl)-5,5-dimethyl-1-(2-morpholinoethyl)imidazolidine-2,4-dione and pharmaceutically acceptable salts thereof, processes for their production, and uses thereof, including in the treatment of ocular diseases and disorders such as dry eye disease and Meibomian gland dysfunction (MGD).

Abstract: Provided is a computer implemented method including receiving a digital communication; analyzing said communication using natural language processing to identify any semantic reference to one or more digital artifacts; and identifying and locating the one or more digital artifacts. In some embodiments one or more digital artifacts are not specifically identified in the digital communication. In some embodiments one or more digital artifacts are not specifically included in the digital communication. Related apparatus, systems, techniques, and articles are also described.

Abstract: Provided is a computer implemented method including receiving a digital communication; analyzing said communication using natural language processing to identify any semantic reference to one or more digital artifacts; and identifying and locating the one or more digital artifacts. In some embodiments one or more digital artifacts are not specifically identified in the digital communication. In some embodiments one or more digital artifacts are not specifically included in the digital communication. Related apparatus, systems, techniques, and articles are also described.

Abstract: There is described a process for the manufacture of compounds of the formula I said process comprising reacting a compound of the formula II as described herein, or a salt thereof, under simultaneous or sequential condensation and cyclisation conditions with an aniline compound of the formula III, wherein R2 and m are as defined for a compound of the formula I. Further reactions and related embodiments are also claimed and disclosed.

Abstract: There is described a new polymorphic form of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile and a method of preparing it.

Abstract: There is described a new polymorphic form of 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile having structural formula I(B) and to a method of preparing it. There is further a process or method for the manufacture of a pharmaceutically active quinazolinone compounds of the formula I wherein the symbols have the meanings given in the description, said process comprising reacting a compound of the formula II, wherein R4* is R1*—C(?O)— wherein R1* is independently selected from the group of meanings of R1 as defined for a compound of the formula I so that R1* and R1 are identical to or different from each other, or R4* is especially H, and R1 and R3, R5 and R6 are as defined for a compound of the formula I, or a salt thereof, under simultaneous or sequential condensation and cyclisation conditions with an aniline compound of the formula III, wherein R2 and m are as defined for a compound of the formula I. Further reactions and related embodiments are also claimed and disclosed.